Analysts don’t see higher bid for Cephalon By: MarketWatch May 02, 2011 at 16:37 PM EDT Cephalon Inc. investors shouldn’t hold their breath for a bid to emerge that tops Teva Pharmaceutical Industries Ltd.’s $81.50-a-share offer, analysts say. Read More >> Related Stocks: Macy's Valeant Pharmaceuticals International, Inc.